October 22, 2016 3:01 AM ET


Company Overview of Intra-Cellular Therapies, Inc.

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia and bipolar depression, as well as to treat behavioral disturbances associated with dementia, sleep disturbances associated with neurologic and psychiatric disorders, sleep and behavioral disturbances associated with autism spectrum disorder, and depression and other mood disorders. The company also develops ITI-002 phosphodiesterase type 1 (PDE1) program that is in phase I ...

430 East 29th Street

Suite 900

New York, NY 10016

United States

37 Employees





Key Executives for Intra-Cellular Therapies, Inc.

Co-Founder, Chairman, Chief Executive Officer and President
Age: 63
Total Annual Compensation: $1.4M
Chief Financial Officer, Vice President of Finance, Treasurer and Assistant Secretary
Age: 60
Total Annual Compensation: $572.8K
Senior Vice President, General Counsel, Corporate Compliance Officer and Secretary
Age: 43
Total Annual Compensation: $680.0K
Senior Vice President of Clinical Development
Age: 50
Total Annual Compensation: $571.2K
Chief Scientific Officer and Senior Vice President
Age: 65
Total Annual Compensation: $222.3K
Compensation as of Fiscal Year 2015.

Intra-Cellular Therapies, Inc. Key Developments

Intra-Cellular Therapies, Inc. - Special Call

Intra-Cellular Therapies, Inc. - Special Call

Intra-Cellular Therapies, Inc. Announces Top-Line Results from the Second Phase 3 Clinical Trial (Study 302) of ITI-007

Intra-Cellular Therapies, Inc. announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the safety and tolerability findings of a previous study (Phase 2 Study 005) in which the efficacy of ITI-007 60 mg and risperidone, the active control, were similar.

Intra-Cellular Therapies, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 01:30 PM

Intra-Cellular Therapies, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 01:30 PM. Venue: The Sofitel New York, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intra-Cellular Therapies, Inc., please visit www.intracellulartherapies.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.